A new gene therapy is effective in treating hemophilia B Bleeding episodes drop by an average 71% following the gene therapy More than half of patients had no bleeds at all after the treatment THURSDAY, Sept. 25, 2024 (HealthDay News) -- A new gene therapy approved earlier this year can serve as a sustainable single-dose treatment for people with hemophilia B, newly published clinical trial data shows. People with hemophilia B saw their bleeding episodes drop by an average 71% following a single infusion of Beqvez (fidanacogene elaparvovec), researchers reported Sept.
25 in the New England Journal of Medicine . Even better, more than half of the study’s 45 patients did not have any bleeds at all after receiving the gene therapy. Hemophilia B is a rare inherited bleeding disorder that causes people to have lower levels of clotting factor IX, a blood protein that helps form clots.
The gene therapy uses a hollowed-out virus to deliver a working copy of the factor IX gene to a patient’s liver, enabling the body to start producing the clotting factor, researchers said. “What we saw from patients in this study was that within a few days of receiving the gene therapy infusion, it took root, and their bodies started making factor IX for the first time in their lives,” said lead researcher Dr. Adam Cuker , clinical director of the Penn Blood Disorders Center and the Penn Comprehensive Hemophilia Program at the University of Pennsylvania.
“We always want to be careful about u.
